My name is Thatcher Ladd and I'm a visiting researcher at Indiana University Purdue University in Indianapolis (IUPUI), and a student of Biology at Oberlin College.
Proof of concept has already been completed.
Long story short: currently, pharmaceutical companies own the patent for the use of SSRI's for depression in humans. If, instead, a person or group of people held that patent, they would be cut a check by pharmaceutical companies seeking to sell SSRI's for more than $780 million every year. I'm seeking to do just that by patenting the next generation of Seasonal Affective Disorder/Atypical Depression (SAD/AD) antidepressants. The drug also has promise to treat some Major Depression, and act far faster than traditional SSRIs.
My drug would: cause no dependence, be impossible to overdose on, cause few if any side effects, AND be the only targeted and efficient SAD/AD drug on the market. It is the next generation of benevolent antidepressants; join me in patenting their use.